statements

Kwality Pharmaceuticals Ltd.

BSE: 539997

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

2,672.50-73.0 (-2.66%)

3 Jul, 3:30 PM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Kwality Pharmaceuticals Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2014 Mar 31	R 2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	59.60	52.38	74.17	98.32	137.49	166.29	139.30	262.01	456.19	251.03	307.17	370.20	503.08
Cost of Operating Revenue	47.37	39.78	57.85	73.73	104.28	122.56	91.51	172.08	211.29	125.03	172.74	200.78	278.24
Gross Profit	12.23	12.60	16.32	24.58	33.22	43.73	47.79	89.93	244.89	126.00	134.43	169.42	224.84
Gross Margin	20.5	24.0	22.0	25.0	24.2	26.3	34.3	34.3	53.7	50.2	43.8	45.8	44.7
Total Operating Expenses	57.27	50.42	70.51	92.00	128.81	153.71	129.54	239.66	295.21	205.85	260.38	308.10	404.65
Operating Profit	2.33	1.95	3.67	6.32	8.68	12.59	9.76	22.36	160.97	45.18	46.79	62.10	98.43
Operating Margin	3.9	3.7	4.9	6.4	6.3	7.6	7.0	8.5	35.3	18.0	15.2	16.8	19.6
Financing Income/(Expense) - Net	-0.72	-1.03	-1.19	-1.88	-2.19	-2.28	-2.50	-2.67	-2.92	-6.02	-10.42	-9.64	-10.97
Profit before Taxes	1.75	1.35	2.48	5.65	7.30	10.91	10.92	21.27	161.57	25.57	31.10	54.14	89.49
Income Taxes	0.81	0.55	1.19	2.37	2.87	3.35	2.71	6.38	41.63	6.29	7.48	14.34	22.15
Profit after Tax	0.93	0.92	1.55	3.36	4.55	7.55	8.32	15.15	119.99	19.37	23.80	39.85	67.35
PAT Margin	1.6	1.7	2.1	3.4	3.3	4.5	6.0	5.8	26.3	7.7	7.7	10.8	13.4
EPS - Basic - ex Extraordinary Items	0.90	0.92	1.55	3.24	4.38	7.28	8.02	14.60	115.64	18.67	22.93	38.40	64.90
EPS - Diluted - ex Extraordinary Items	0.90	0.92	1.55	3.24	4.38	7.28	8.02	14.60	115.64	18.67	22.93	38.40	64.90
EBIT	2.33	1.95	3.67	6.32	8.68	12.59	9.76	22.36	160.97	45.18	46.79	62.10	98.43
EBITDA	3.53	3.26	5.36	8.82	11.66	15.71	14.19	28.85	171.66	60.14	66.35	80.39	118.24
EBITDA Margin	5.9	6.2	7.2	9.0	8.5	9.4	10.2	11.0	37.6	24.0	21.6	21.7	23.5

Balance Sheet

Abridged

Understanding Balance Sheet

Kwality Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2014 Mar 31	R 2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	PR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	22.34	24.46	38.19	53.07	75.00	75.35	89.03	105.90	227.82	207.20	242.69	283.78	405.68
Long-Term Investments	0.14	0.03	0.03	0.62	0.63	0.79	0.65	0.73	-	-	-	-	-
Property Plant & Equipment - Net	12.64	12.74	12.72	17.01	20.38	29.08	42.69	59.42	103.88	134.79	139.05	143.98	166.73
Total Non-Current Assets	12.78	12.86	13.01	17.85	21.21	30.03	43.66	60.36	112.77	146.43	151.52	163.49	186.53
Total Assets	35.12	37.32	51.20	70.92	96.20	105.38	132.69	166.26	340.59	353.63	394.21	447.27	592.21
Total Current Liabilities	15.27	17.41	26.54	41.60	61.98	60.83	67.75	78.29	139.49	125.95	151.85	169.50	225.52
Long Term Debt	1.41	0.80	2.70	3.30	4.71	7.59	10.18	18.26	20.29	27.30	19.56	15.12	29.40
Total Non-Current Liabilities	2.10	0.83	3.32	4.24	5.47	8.23	19.98	28.12	21.32	28.62	19.78	15.37	36.77
Total Liabilities	17.37	18.24	29.86	45.83	67.44	69.07	87.73	106.41	160.80	154.56	171.63	184.88	262.29
Total Shareholders' Equity	17.78	19.22	21.76	25.58	29.75	37.30	46.01	61.15	181.14	200.52	224.21	264.05	331.60
Minority Interest	-0.03	-0.14	-0.41	-0.50	-0.99	-0.98	-1.04	-1.30	-1.35	-1.45	-1.63	-1.65	-1.67
Total Equity	17.75	19.08	21.34	25.09	28.76	36.32	44.96	59.85	179.79	199.07	222.58	262.40	329.92
Total Liabilities & Equity	35.12	37.32	51.20	70.92	96.20	105.38	132.69	166.26	340.59	353.63	394.21	447.27	592.21

Cash Flow

Abridged

Understanding Cash Flow Statement

Kwality Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2014 Mar 31	R 2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	2.52	2.02	3.29	6.16	6.56	10.59	13.02	21.49	130.98	34.47	56.35	56.63	89.15
Working Capital - Increase/(Decrease)	-4.01	-1.89	-7.31	-3.61	-9.17	0.89	-9.13	2.72	-73.18	1.01	-23.44	-13.64	-83.40
Net CF from Operating Activities	-1.49	0.13	-4.02	2.55	-2.61	11.48	3.89	24.22	57.80	35.48	32.92	43.00	5.74
Capital Expenditures - Net	3.31	1.36	2.46	6.79	6.33	11.82	17.93	23.26	55.15	45.81	25.73	24.93	45.70
Net CF from Investing Activities	-3.31	-1.36	-2.49	-7.38	-6.35	-11.97	-18.03	-23.38	-63.05	-48.56	-26.53	-28.67	-35.04
Dividends Paid - Cash - Total	-	-	-	0.31	-	-	-	-	-	-	-	-	-
Stock - Issuance/(Retirement) - Net	-	-	-	0.18	-	-	-	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-0.38	2.01	4.92	6.04	7.64	0.28	5.09	3.44	8.57	7.01	-7.20	-4.56	18.01
Net Cash Flow from Financing Activities	3.77	2.01	6.82	6.48	7.58	0.28	14.27	3.44	8.57	7.01	-7.20	-4.56	18.01
Free Cash Flow to Equity	-5.19	0.79	-1.56	1.80	-1.30	-0.05	-8.95	4.40	11.22	-3.31	-0.01	13.51	-21.95
Free Operating CF net dividend	-4.80	-1.31	-6.61	-4.56	-8.96	-0.34	-16.88	0.82	2.65	-12.19	3.08	18.00	-43.20
Free Operating CF	-4.80	-1.31	-6.61	-4.25	-8.96	-0.34	-16.88	0.82	2.65	-12.19	3.08	18.00	-43.20

Business Segment Analysis

FY End:

Mar 25

Kwality Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 25.00 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 370.20 Cr

Assets

Pharmaceuticals (100.0%)₹ 447.27 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 62.10 Cr

Regional Segment Analysis

Kwality Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Kwality Pharmaceuticals Ltd.

Historical Segment Analysis

Track how Kwality Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2024 Mar 31	2025 Mar 31

Pharmaceuticals	30	25

Frequently Asked Questions

What is the revenue of Kwality Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of Kwality Pharmaceuticals Ltd. is ₹ 503.08 Cr, reflecting a 1-year growth of 35.90% and a 3-year CAGR of 26.08%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Kwality Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of Kwality Pharmaceuticals Ltd. is ₹ 67.35 Cr, with a 3-year earnings CAGR of 51.48%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Kwality Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of Kwality Pharmaceuticals Ltd. is approximately ₹ 98.43 Cr (based on an operating margin of 19.57%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Kwality Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Kwality Pharmaceuticals Ltd. is 64.90. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Kwality Pharmaceuticals Ltd.?

The debt-to-equity ratio of Kwality Pharmaceuticals Ltd. stands at 0.39. The interest coverage ratio is 8.97x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Kwality Pharmaceuticals Ltd.?

The estimated book value per share of Kwality Pharmaceuticals Ltd. is 307.89 (derived from a P/B ratio of 8.68 and market price of ₹ 2,672.50), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Kwality Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of Kwality Pharmaceuticals Ltd. is ₹ 5.74 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Kwality Pharmaceuticals Ltd. report consolidated or standalone financials?

Kwality Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.